samedan logo
 
 
 
spacer
home > pmps > winter 2001 > biopharma process systems from a land flowing with milk and wine - the demand for high-tech biomanufacturing equipment
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Biopharma Process Systems from a Land Flowing With Milk and Wine - The Demand For High-Tech Biomanufacturing Equipment

Q Denis, tell me how BIOLAFITTE & MORITZ evolved?A My father founded PIERRE GUERIN in 1949 at Mauzé-sur-le-Mignon, in the heart of the first milk- and cheese-producing region in France. It was a family business where we designed and produced stainless steel processvessels, pumps, valves, agitation and mixing systems for the food processing industry (such as milk desserts, fresh products, ice creams, yoghurts, pressed cheeses and wine vintages). Then it transferred its knowledge of hygiene and processing vats for the food industry to the pharmaceutical and cosmetic industries and more recently to the biotechnology industry.

In November 1998, PIERRE GUERIN S.A. acquired the company BIOLAFITTE,

consolidating its own knowledge and reputation within the biotechnology industry. Recently created, the division BIOLAFITTE & MORITZ, became a leader in the biopharmaceutical sector.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
As a predicted shortfall in production capacity for proteins (for example, monoclonal antibodies), compels the biopharmaceutical sector to consider its supply strategy for the next five years, the manufacturers of process equipment are at the front line ready to meet the demand for more sophisticated vessels and process control equipment. A leading supplier of biopharmaceutical process systems is BIOLAFITTE & MORITZ, based in Mauzй, France. Dr Patricia Lobo, Editor of PMPS, visits BIOLAFITTE & MORITZ to meet Denis Guerin, Senior Project Engineer, Daniel Blanchi, Director and Doru Felezeu, International Director of the company.
spacer
Denis Guerin
spacer
spacer
spacer
Daniel Blanchi
spacer
spacer
spacer
Doru Felezeu
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Significant improvement in overall survival with ERLEADA®▼ (apalutamide) for patients with non-metastatic castration-resistant prostate cancer

BEERSE, BELGIUM, May 14, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the final analysis of the pivotal Phase 3 SPARTAN study demonstrating ERLEADA®▼ (apalutamide) in combination with androgen deprivation therapy (ADT) significantly improved overall survival (OS), compared to ADT alone, in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who were at high risk of developing metastases.1 Results will be presented at the American Society of Clinical Oncology (ASCO) Virtual Scientific Programme (Abstract #5516) beginning on Friday 29th May.
More info >>

White Papers

Autoinjector testing made safe efficient and flexible

ZwickRoell

The autoinjector market is one of the fastest growing markets across almost all pharmaceutical applications. Studies expect a global market volume of approximately USD 2.5 billion by 2020, with pre-filled autoinjectors representing the largest market segment. There are a variety of tests that can be performed on autoinjectors, and these are well-demonstrated by the Zwick product portfolio. The Ulm-based company and specialist in testing systems offers a variety of testing systems that are already being successfully used by multiple pharmaceutical companies.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement